EHRA 2023: Late-Breaking Science Video Collection
Published: 18 April 2023
6m 25sPart 2 | Session 1 5 Trials That Will Change Your Practice With Dr Sohaib
6m 24sPart 2 | Session 2 4 Trials That Will Change Your Practice With Dr Di Biase
54sPart 3 | Session 1 Dr Bergonti: Pulsed-Field Ablation & Reasons to Research
1m 52sPart 3 | Session 2 Dr Bruce Wilkoff: Therapy Morbidity and Advice to Young Researchers
31sPart 3 | Session 3 Dr Carlo Pappone: Advice to Early-Career Electrophysiologists
28sPart 3 | Session 4 Dr Juan Caro Codon: Building a Team For Success
4m 23sPart 1 | Session 1 POTTER: Oesophageal Fistulae in Catheter Ablation Patients Roland R Tilz
4m 26sPart 1 | Session 2 AdaptResponse: AdaptivCRT® Algorithm in Synchronized LV Pacing Bruce Wilkoff
6m 49sPart 1 | Session 3 MANIFEST-PF: Real-world Experience of PFA in Commercial Practice Vivek Reddy
6m 26sPart 1 | Session 4 ANTWOORD II: LVEF Recovery After Atrial Fibrillation Ablation in Heart Failure Patients Marco Bergonti
2m 38sPart 1 | Session 5 TEMPO-HCM: Extended ECG Monitoring in HCM Juan Caro Codón
3m 37sPart 1 | Session 6 Conformable PVI Catheter for Pulmonary Vein Isolation Vivek Reddy
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research and clinical practice.
More from this programme
In these concise overviews, selected faculty provide their thoughts on the most impactful trials from EHRA 2023.
Behind the Heart
Watch our Behind the Heart series to learn more about the personal perspectives of the investigators behind top trials in cardiovascular science.
About the episode
EHRA 23 - We are joined onsite by Prof Carlo Pappone (IRCCS Policlinico San Donato, IT) who outlines the key findings of the BRUGADA Randomized trial.
In a randomized controlled trial, 150 patients with Brugada syndrome were enrolled in to develop an evidence-based treatment for the condition. Patients were randomized in a 2:1 fashion to receive either catheter ablation treatment with an ICD, or an ICD alone to evaluate the effectiveness of epicardial ablation in reducing rates of sudden cardiac death.
- What is the reasoning behind this study?
- What are the unmet needs in the treatment of Brugada Syndrome?
- What was the study design and patient population?
- What are the key findings?
- What could be the impact of these results on clinical practice?
- What further research is needed?
Recorded at EHRA 2023, Barcelona.
Director, Clinical Arrhythmology and Electrophysiology
Dr. Carlo Pappone is currently Director of the Department of Arrhythmology at the Hospital San Raffaele in Milan, Italy.
He is author of more than 140 peer-reviewed papers, related to many areas of Cardiology specialty. He is member of the editorial board/consultant Reviewer of several scientific journals, like Circulation, Circulation AE, JACC, NEJM, Lancet, JAMA, Heart Rhythm, etc. His main interest is cardiac electrophysiology and catheter ablation of all types of arrhythmias including Brugada syndrome as well as electrical devicetherapy for patients with heart failure.
Dr Pappone is a member of the Arrhythmia & Electrophysiology Review editorial board.